Compare CMBM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMBM | LEXX |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 22.7M |
| IPO Year | 2019 | N/A |
| Metric | CMBM | LEXX |
|---|---|---|
| Price | $1.62 | $0.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.5M | 315.2K |
| Earning Date | 02-19-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,215,000.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | $18.01 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.23 | $0.66 |
| 52 Week High | $6.80 | $2.43 |
| Indicator | CMBM | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 28.90 |
| Support Level | $1.41 | $1.05 |
| Resistance Level | $1.69 | $1.44 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 27.45 | 10.94 |
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.